Title: Use of RNA Interference to Validate New Termiticide Target Sites and a Method of Termite Control
Patent Number: 7,968,525
Filed: Nov. 26, 2008
Lead Inventor: Michael Scharf, University of Florida
The invention, the patent's abstract states, comprises “methods, matrix compositions, and kits for increasing the mortality of termites and interfering with termite development using RNA interference techniques to target cellulase, lignocellulase, hexamerin, broad, farnesoic acid methyl transferase, cytochrome P450, and vitellogenin activity.”
Title: Furin Knockdown Bi-Functional RNA
Application Number: 20110150832
Filed: Dec. 20, 2010
Lead Inventor: John Nemunaitis, Gradalis
The patent application, its abstract states, claims “compositions and methods to attenuate the immunosuppressive activity of TGF-beta through the use of bi-functional shRNAs. ... The bi-functional shRNAs … [knock] down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.”
Title: Amphiphilic Block Co-Polymers for Nucleic Acid Delivery
Application Number: 20110151013
Filed: May 14, 2009
Lead Inventor: Andrew Lennard Lewis, Biocompatibles UK
The invention comprises “a composition comprising vesicles and encapsulated … nucleic acid comprising less than 1,000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block,” the patent application's abstract states. “Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided.”
Title: Virus-Specific miRNA Signatures for Diagnosis and Therapeutic Treatment of Viral Infection
Application Number: 20110151430
Filed: March 4, 2010
Lead Inventor: Timothy Kowalik, University of Massachusetts
The invention, the patent application's abstract states, relates to microRNA “signatures and diagnostic and therapeutic applications of miRNA signatures. The miRNA signatures are defined by a test sample miRNA profile relative to an appropriate control miRNA profile. In some embodiments, the test sample is a sample isolated, obtained, or derived from a virus-infected cell or organism.
“The ... invention further relates to the use of miRNA signatures in the identification of druggable targets and antiviral agents,” the abstract adds. “Kits and compositions are also provided.”
Title: shRNA-Mediated Inhibition of Expression of Alpha-1,6-Fucosyltransferase
Application Number: 20110151513
Filed: Dec. 1, 2010
Lead Inventor: Vincent Beuger, Roche
The invention comprises “a method for producing a heterologous polypeptide with a reduced degree of fucose modification in a mammalian cell by cultivating the mammalian cell under conditions suitable for the expression of said heterologous polypeptide, and recovering the heterologous polypeptide from the mammalian cell or the culture, wherein in said mammalian cell the enzymatic activity of alpha-1,6-fucosyltransferase is reduced by means of an shRNA directed against alpha-1,6-fucosyltransferase mRNA,” the patent application's abstract states.
Title: Methods and Compositions for Reducing Target Gene Expression Using Cocktails of siRNAs or Constructs Expressing siRNAs
Application Number: 20110151558
Filed: March 3, 2011
Lead Inventor: David Brown, Life Technologies
The invention, the patent application's abstract states, “concerns methods and compositions involving the production or generation of siRNA mixtures or pools capable of triggering RNA-mediated interference in a cell. Compositions of the invention include kits that include reagents for producing or generating siRNA pools.
“The ... invention further concerns methods using polypeptides with RNase III activity for generating siRNA mixtures or pools that effect RNAi, including the generation of a number of RNA molecules to the same target gene,” it adds.
Title: Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids
Application Number: 20110152346
Filed: Nov. 5, 2008
Lead Inventor: Mati Karleson, Baltic Technology Development
“The invention is concerned with the use of oligonucleotide analogs that contain specifically modified DNA bases to be used in hybridization of nucleic acids, polymerase chain reaction, and siRNA-mediated gene silencing,” the patent application's abstract states.
Title: Methods and Compositions for Controlling Efficacy of RNA Silencing
Application Number: 20110152347
Filed: June 7, 2010
Lead Inventor: Phillip Zamore, University of Massachusetts
“Based at least in part on an understanding of the mechanisms by which small RNAs mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, [and] the effect of the position of the mismatches,” the patent application's abstract states. “Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.”
Title: Compositions and Methods for Inhibiting Expression of IL-18 Genes
Application Number: 20110152349
Filed: Dec. 14, 2010
Lead Inventor: Anke Geick, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of [an] IL-18 gene,” the patent application's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of [an] IL-18 gene using said pharmaceutical composition; and methods for inhibiting the expression of IL-18 in a cell.”
Title: Compositions and Methods for Inhibiting Expression of XBP-1 Gene
Application Number: 20110152350
Filed: Dec. 16, 2010
Lead Inventor: Kevin Fitzgerald, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1,” the patent application's abstract states.
Title: SMAD Proteins Control Drosha-Mediated miRNA Maturation
Application Number: 20110152352
Filed: June 10, 2009
Lead Inventor: Akiko Hata, Tufts University
“The invention, in some aspects, relates to compositions and methods useful for modulating expression of miRNAs that are regulated by the TGF-beta/BMP signaling pathway,” the patent application's abstract states.
“In some aspects, the invention relates to oligonucleotides comprising a CAGRN-motif that modulate expression of miRNAs that are regulated by TGF-beta/BMP signaling pathway.”
In other aspects, it relates to a “composition and methods useful for inhibiting microRNA processing,” or a composition and methods for treating TGF-beta/BMP-mediated disorders, it adds.
Title: Double-Stranded Polynucleotide
Application Number: 20110152353
Filed: June 30, 2009
Lead Inventor: Makoto Moizumi, Daiichi Sankyo
The invention, the patent application's abstract states, comprises “a double-stranded polynucleotide that is resistant to RNase and has [an] RNA interference effect. ... The ... double-stranded polynucleotide [is made of] sense and antisense strands comprising polynucleotides comprising a nucleotide unit of DNAs and 2'-O-methyl RNAs alternately combined.”
Title: Novel RNAi Therapeutics for Treatment of Hepatitis C Infection
Application Number: 20110152356
Filed: Feb. 28, 2011
Inventor: Hengli Tang, Florida State University
The invention comprises “small interfering RNAs or small hairpin RNA and compositions ... that specifically target human cyclophilin A to effectively inhibit hepatitis C infection in a cell,” according to the patent application's abstract. “Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A cDNA .”
Title: microRNA-Based Composition and Methods for the Diagnosis, Prognosis, and Treatment of Multiple Myeloma
Application Number: 20110152357
Filed: Aug. 12, 2009
Inventor: Carlo Croce, Ohio State University
The invention, the patent application's abstract states, comprises “methods for assessing a pathological condition in a subject, [which] includes measuring an expression profile of one or more markers where a difference is indicative of multiple myeloma or a predisposition to” the disease. The invention provides “novel methods and compositions for the diagnosis, prognosis and treatment of” multiple myeloma and methods of identifying anti-cancer agents.